Methylxanthine treatment for apnoea in preterm infants

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 12, 2010, Pages

  Henderson Smart, David J ^c   De Paoli, Antonio G ^a   Haughton, Diane ^b  

^a ROYAL HOBART HOSPITAL   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; CAFFEINE; METHYLXANTHINE; PLACEBO; THEOPHYLLINE; CENTRAL STIMULANT AGENT; VASODILATOR AGENT; XANTHINE DERIVATIVE;

APNEA; BIRTH WEIGHT; CEREBRAL PALSY; CHILD DEATH; CHRONIC LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COGNITIVE DEFECT; DISABILITY; DRUG EFFECT; EVIDENCE BASED MEDICINE; GESTATIONAL AGE; HUMAN; INCIDENCE; INFANT; INTERMITTENT POSITIVE PRESSURE VENTILATION; OUTCOME ASSESSMENT; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT FAILURE; META ANALYSIS; NEWBORN; RANDOMIZED CONTROLLED TRIAL (TOPIC);

APNEA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTERMITTENT POSITIVE-PRESSURE VENTILATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THEOPHYLLINE; VASODILATOR AGENTS; XANTHINES;

EID: 79952197647     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000140.pub2     Document Type: Review

References (24)

1. Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R, Sinha S, Tin W, Caffeine for Apnea of Prematurity Trial Group. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. Journal of Pediatrics 2010;156(3):382-7.
2. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. New England Journal of Medicine 2006;354(20):2112-21.
3. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. New England Journal of Medicine 2007;357(19):1893-902.
4. Erenberg A, Leff R, Wynne B. Results of the first double blind placebo (PL) controlled study of caffeine citrate (CC) for the treatment of apnea of prematurity (AOP). Pediatric Research 1998;43:172A.
5. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a double-blind placebo-controlled study. Pharmacotherapy 2000;20(6):644-52.
6. Gupta JM, Mercer HP, Koo WWK. Theophylline in treatment of apnoea of prematurity. Australian Paediatric Journal 1981;17(4):290-1.
7. Murat I, Moriette G, Blin MC, Couchard M, Flouvat B, De Gamarra E, et al.The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. Journal of Pediatrics 1981;99(6):984-99.
8. Peliowski A, Finer NN. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. Journal of Pediatrics 1990;116(4):648-53.
9. Sims ME, Yau G, Rambhatla S, Cabal L, Wu PYK. Limitations of theophylline in the treatment of apnea of prematurity. American Journal of Diseases of Children 1985;139(6):567-70.
10. Charles BG, Townsend SR, Steer PA, Flenady VJ, Gray PH, Shearman A. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Therapeutic Drug Monitoring 2008;30(6):709-16.
11. Hochwald C, Kennedy K, Chang J, Moya F. A randomized, controlled, double-blind trial comparing two loading doses of aminophylline. Journal of Perinatology 2002;22(4):275-8.
12. Committee on Fetus and Newborn. American Academy of Pediatrics. Apnea, sudden infant death syndrome, and home monitoring. Pediatrics 2003;111(4 Pt 1):914-22.
13. Blanchard PW, Aranda JV. Pharmacotherapy of respiratory control disorders. In: Beckerman RC, Brouillette RT, Hunt CE editor(s). Respiratory Control Disorders in Infants and Children. Baltimore: Williams & Wilkins, 1992:352-370.
14. Comer AM, Perry CM, Figgitt DP. Caffeine citrate: a review of its use in apnoea of prematurity. Paediatric Drugs 2001;3(1):61-79.
15. Davis PG, Doyle LW, Rickards AL, Kelly EA, Ford GW, Davis NM, Callanan C. Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight. Journal of Paediatrics and Child Health 2000;36(1):47-50.
16. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthine for extubation in preterm infants. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: ]
17. Henderson-Smart DJ, Steer P. Prophylactic methylxanthine for the prevention of apnea in preterm infants. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: ]
18. Henderson-Smart DJ. Recurrent apnoea. Evidence Based Pediatrics. Oxford: Blackwell, 2004.
19. Steer P, Henderson-Smart DJ. Caffeine vs theophylline treatment for apnea in preterm infants. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: ]
20. Martin RJ, Fanaroff AA. Neonatal apnea, bradycardia, or desaturation: does it Matter?. Journal of Pediatrics 1998;132(5):758-759.
21. Samuels MP, Southall DP. Recurrent apnea. In: Sinclair JC, Bracken MB editor(s). Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992:385-97.
22. Schmidt B. Methylxanthine therapy in premature infants: sound practice, disaster or fruitless byway?. Journal of Pediatrics 1999;135(4):526-8.
23. Henderson-Smart DJ, Steer P. Methylxanthine for apnea in preterm infants. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: ]
24. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: ]